Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren's disease

Loïc Meudec; Negaar Goudarzi; Sacha E Silva-Saffar; Juliette Pascaud; Fanny Jaulin; Quentin Pascal; Thierry Lazure; Rami Bechara; Xavier Mariette; Gaetane Nocturne

doi:10.1016/j.ard.2025.04.020

Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren's disease

Ann Rheum Dis. 2025 May 19:S0003-4967(25)00909-4. doi: 10.1016/j.ard.2025.04.020. Online ahead of print.

Authors

Affiliations

¹ Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Inserm UMR 1184, Le Kremlin-Bicêtre, France; Department of immuno-rhumatology, FHU CARE 2, AP-HP, GHU Paris Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
² Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Inserm UMR 1184, Le Kremlin-Bicêtre, France.
³ Institut Gustave Roussy, INSERM U1279, Patient-Derived Cancer Organoids Platform, Université Paris Saclay, Villejuif, France.
⁴ Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Le Kremlin-Bicêtre, France.
⁵ Department of pathology, AP-HP, GHU Paris Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
⁶ Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Inserm UMR 1184, Le Kremlin-Bicêtre, France; Department of immuno-rhumatology, FHU CARE 2, AP-HP, GHU Paris Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. Electronic address: gaetane.nocturne@aphp.fr.

PMID: 40393919
DOI: 10.1016/j.ard.2025.04.020

Abstract

Objectives: Salivary gland epithelial cells (SGECs) play a key role in Sjögren's disease (SjD) as an active contributor to the pathogenesis. Current models lack clear epithelial readouts. Our aim was to establish a more advanced model by developing salivary gland organoids (SGOs) from labial salivary gland biopsies (LSGBs) of SjD patients and sicca controls.

Methods: We included SjD patients fulfilling the American College of Rheumatology/European League Against Rheumatism 2016 criteria and sicca controls. LSGBs were dissociated, encapsulated in extracellular matrix, and submerged in growth expansion medium for long-term culture. SGOs were primarily cultured in differentiation medium and then transferred to a low attachment plate to form differentiated SGOs (DIF-SGOs).

Results: We included 13 SjD and 15 controls. In both groups, SGOs were formed, demonstrating long-term culture viability and comparable self-renewal capacity (3.3 ± 1.7 months). DIF-SGOs comparably exhibited mature acinar (aquaporin 5, amylase), ductal (cytokeratins 5 and 7) and myoepithelial (α-smooth muscle actin) markers in both groups. DIF-SGOs were responsive to inflammation by expressing BAFF, CXCL10 and IL7 upon stimulation with poly(I:C) and interferon-α. DIF-SGOs also demonstrated a swelling response to cholinergic stimulation by pilocarpine. We observed significant differences between SjD- and control-derived SGOs. Notably, SjD-derived DIF-SGOs consistently maintained a persistent interferon signature throughout long-term culture. In addition, the swelling capacity was reduced in SjD-derived DIF-SGOs compared to control. However, treatment with tofacitinib enhanced the swelling ability, suggesting a potential effect on saliva production.

Conclusions: We successfully developed SGOs from LSGBs of SjD patients, allowing long-term culture and faithfully recapitulating the disease phenotype. This model holds promise as a valuable tool for drug screening.